VXRT - Vaxart starts enrollment in early-stage norovirus boosting regimen study

Vaxart ([[VXRT]] +16.3%) announces that it has enrolled the first subject in a Phase 1b boosting regimen trial of its norovirus vaccine candidate.The Phase 1b study is designed to enroll 30 subjects aged 18 to 55 years old, with endpoints being safety and immunogenicity.Subjects will be randomized into 3 cohorts: Cohort 1 will receive the vaccine candidate on day 1 and week 4; Cohort 2 will receive the vaccine candidate on day 1 and week 8; Cohort 3 will receive the vaccine candidate on day 1 and week 12.Norovirus is a potentially fatal illness that affects around 20M Americans annually.The booster regimen trial is the second of four Vaxart norovirus trials that are ongoing or are planned for 2021.The company is also scheduled to initiate an age escalation trial in subjects over 65 years old and plans to launch a Phase 2 challenge study later this year.New data obtained from Vaxart's Phase

For further details see:

Vaxart starts enrollment in early-stage norovirus boosting regimen study